囊肿纤维化药物市场规模、份额和成长分析（按药物类别、给药途径、分销管道和地区）- 产业预测 2025-2032

2023 年囊肿纤维化药物市场规模价值 65 亿美元，预计将从 2024 年的 74.2 亿美元成长到 2032 年的 213.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 14.1%。

随着囊性纤维化 (CF) 盛行率的上升和治疗率的提高，囊肿纤维化(CF) 药物市场预计将经历显着增长。公共和私营部门对研发的资金筹措增加以及强有力的非营利措施进一步支持了市场扩张。随着患者数量逐年增加，对有效治疗方法的需求也随之增加，现有药物类别（如 CFTR 调节剂、黏液溶解剂和抗生素）的利用率也随之增加。此外，各大製药公司不断增加的创新治疗药物和旨在扩大客户群的持续研究也促进了市场的发展。一些慈善组织积极支持 CF 研究和发展也是推动市场成长的关键因素。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 技术分析

囊肿纤维化药物市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概况
• 抗感染药物
• CFTR调变器
• 胰酵素补充剂
• 黏液溶解剂
• 支气管扩张剂

囊肿纤维化药物市场规模（依给药途径及复合年增长率） (2025-2032)

• 市场概况
• 口服
• 吸入

囊肿纤维化药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局

囊肿纤维化药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Vertex Pharmaceuticals（USA）
• AbbVie（USA）
• Gilead Sciences（USA）
• Roche（Switzerland）
• Teva Pharmaceutical Industries（Israel）
• Mylan（now Viatris）（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Alaxia.
• Allergan（now part of AbbVie）（Ireland）
• Beyond Air Inc.（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co. Inc.（USA）
• Alcresta Therapeutics Inc.（USA）
• Chiesi（Italy）
• Nestle HealthScience（Switzerland）
• Pharmaxis Ltd.（Australia）
• PTC Therapeutics, Inc.（USA）
• Insmed, Inc.（USA）
• Grifols SA（Spain）

结论和建议

Cystic Fibrosis Therapeutics Market size was valued at USD 6.5 billion in 2023 and is poised to grow from USD 7.42 billion in 2024 to USD 21.31 billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).

The cystic fibrosis (CF) therapeutics market is poised for significant growth driven by the rising prevalence of CF and an increase in treatment rates. Enhanced funding for research and development from both public and private sectors, along with robust nonprofit initiatives, is further propelling market expansion. The demand for effective therapies is increasing due to a year-on-year rise in patient numbers, leading to greater utilization of existing drug classes, including CFTR modulators, mucolytics, and antibiotics. Additionally, a growing pipeline of innovative therapy compositions from leading pharmaceutical companies and ongoing studies aimed at broadening their customer base will contribute to market dynamics. The active role of several charitable organizations in supporting CF research and development is also a crucial factor in fostering market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cystic Fibrosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cystic Fibrosis Therapeutics Market Segments Analysis

Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, PancreaticenzymeSupplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is predominantly driven by the rising incidence of cystic fibrosis, a genetic disorder that significantly impacts the respiratory, digestive, and reproductive systems. As this debilitating condition remains incurable, patients necessitate continuous treatment throughout their lives, which in turn fuels the demand for effective cystic fibrosis therapeutics. As more individuals are diagnosed and require ongoing care, the market is expected to see substantial growth, underscoring the critical need for innovative treatments and supportive therapies to enhance the quality of life for those affected by this chronic illness.

Restraints in the Cystic Fibrosis Therapeutics Market

The elevated prices associated with cystic fibrosis treatments, especially innovative targeted therapies, pose a significant challenge to patient access. This situation raises crucial concerns regarding the affordability of these essential medications and their influence on healthcare systems. Many patients are unable to obtain necessary treatments due to the financial burden, which can lead to potential disparities in healthcare outcomes. As a result, these high costs not only affect individual patients but also strain the resources of healthcare providers and insurers, ultimately complicating the management of cystic fibrosis and limiting the overall efficacy of available therapies.

Market Trends of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genomic research and a deeper understanding of the disease's genetic underpinnings. As more targeted therapies emerge that cater to specific mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, patients are increasingly seeking tailored treatment options that provide enhanced efficacy and improved outcomes. This trend is anticipated to escalate, encouraging pharmaceutical companies to invest in innovative research and development, ultimately transforming cystic fibrosis management. Consequently, a robust growth trajectory is expected in the personalized medicines segment, solidifying its prominence in the evolving therapeutics landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis

Global Cystic Fibrosis Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-infectives
• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

Global Cystic Fibrosis Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Inhaled

Global Cystic Fibrosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cystic Fibrosis Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Route Of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route Of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route Of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route Of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route Of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (now Viatris) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alaxia.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (now part of AbbVie) (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beyond Air Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcresta Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle HealthScience (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaxis Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations